Description

Lisinopril Tablet

Lisinopril Tablets USP / BP / IP (5 mg / 10 mg / 20 mg)

Direct-Acting Angiotensin-Converting Enzyme (ACE) Inhibitor

Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a leading Indian manufacturer, CDMO services provider, and wholesale exporter of advanced cardiovascular, renal, and metabolic health therapeutics. We manufacture a comprehensive, internationally standardized range of Lisinopril Tablets inside our state-of-the-art, WHO–GMP certified, high-capacity solid dosage manufacturing facilities.

Serving as a primary frontline therapeutic baseline for hypertension, congestive heart failure, and post-myocardial infarction stabilization, this essential public health commodity represents a massive-volume strategic asset for national health ministries, state hospital purchasing networks, retail pharmacy distribution chains, and digital B2B marketplaces across the CIS region, Africa, LATAM, and South-East Asia.

Product Overview

This formulation operates as a “Direct Systemic Vasodilator & Renin-Angiotensin System Suppressor.” It ensures long-term cardiovascular stability and kidney protection by directly stopping the production of the hormones that force blood vessels to dangerously tighten.

• Mechanism 1 (Direct ACE Inactivation): Lisinopril physically binds to and competitively inhibits Angiotensin-Converting Enzyme (ACE). Because it is a non-prodrug, it does not require hepatic activation and acts immediately within systemic circulation.

• Mechanism 2 (Angiotensin II Suppression): By inactivating the ACE enzyme, it completely halts the chemical conversion of Angiotensin I into Angiotensin II (a potent vasoconstrictor). This reduction in Angiotensin II concentrations forces peripheral arteries to dilate, dropping systemic vascular resistance and decreasing arterial blood pressure.

• Mechanism 3 (Bradykinin Potentiation & Cardiac Unloading): It simultaneously blocks the breakdown of Bradykinin (a natural vasodilating peptide). The physical buildup of bradykinin further expands blood vessels and reduces aldosterone secretion, which helps clear excess sodium and fluid to significantly lower cardiac workload (preload and afterload).

Product Composition & Available Portfolio Range

We manufacture Lisinopril in exact, compendial strengths calibrated to support initial introductory titration up to high-potency cardioprotective maintenance blocks.

Technical & Logistics Specifications

• HS Code: 3004.90.79 (Medicaments acting on the cardiovascular system / Anti-hypertensives / ACE Inhibitors) or 3004.90.99 (General Category)

• CAS Number: 83915-83-7 (Lisinopril Dihydrate) / 76547-98-3 (Lisinopril Anhydrous)

• Dosage Form: Oral Solid Tablet (Precisely engineered with clear compendial score lines for exact dosage fractioning when required)

• Packaging Configurations: 10 / 14 / 15 / 28 Tablets per Blister Strip packed in high-barrier Alu-Alu (Cold-Form Foil) or premium moisture-shield PVC/PVDC strips. Lisinopril is sensitive to atmospheric moisture; our tropicalized packaging completely shields the active core matrix, guaranteeing a stable 36-month shelf life in hot, humid Zone IVb export environments.

High-Output Granulation Technology & Quality Attributes

                 [ LISINOPRIL DIHYDRATE ACTIVE API ]
                                │
                                ▼
           [ HIGH-SHEAR WET GRANULATION ISO-BLOCK ]
                                │ (Relative humidity strictly held below 40%)
                                ▼
            [ AUTOMATED ROTARY COMPRESSION MATRIX ]
                                │ (Online multi-point punch weight control)
         ┌──────────────────────┴──────────────────────┐
         ▼                                             ▼
 [ FLUSH EXTRA-LOW TOLERANCE ]             [ BIOEQUIVALENCE曲线 SYNC ]
 Flawless Content Uniformity (<3% CV)      Targeted 24-Hour Dissolution Stability

• Advanced High-Shear Fluid Granulation Processing: Lisinopril raw materials require uniform particle binding to prevent tablet capping. Our processing suites utilize Advanced High-Shear Mixers and Fluid Bed Dryers, physically densifying the powder blend into homogeneous granules. This eliminates density variations and guarantees absolute content uniformity across high-output compression runs.

• Zero-Segregation Compression Uniformity: To satisfy multi-million unit state tenders, our automated tablet presses run with Forced Feeder Die Matrices and Online Weight-Verification Controls, physically ensuring that every single tablet contains an exact therapeutic payload.

• In-Vitro Dissolution Profiling: Every production batch physically undergoes strict Automated Multi-pH Dissolution Profiling, chemically validating that our generic solid doses match the precise bioequivalence curves and release kinetics of global innovator references (such as Prinivil / Zestril).

Primary Indications

• Cardiology & Hypertension: Frontline treatment of Essential Hypertension and secondary renovascular hypertension, both as monotherapy and in combination with other antihypertensive agents.

• Congestive Heart Failure: Adjuvant therapy alongside digitalis and diuretics for the management of Congestive Heart Failure (CHF) to improve survival rates.

• Post-Myocardial Infarction Care: Early intervention treatment within 24 hours of an acute Myocardial Infarction (Heart Attack) to prevent left ventricular dysfunction and secondary cardiac failure propagation.

Usage Instructions

• The 24-Hour Administration Window: Take the tablet orally once daily at approximately the same time each day with a full glass of water. It can be administered consistently either with or without food.

• The Initial Dosing First-Drop Rule: The very first dose of Lisinopril may induce a sudden orthostatic blood pressure drop (first-dose hypotension), especially in patients using concurrent diuretics. It is clinically recommended to administer the introductory dose at bedtime or under close physical observation.

• The Dry Cough Chemical Note: Advise pharmacy and clinical networks that ACE inhibitors prevent the degradation of bradykinin in respiratory pathways, which physically triggers a persistent, benign dry cough in approximately 5% to 10% of patients. If this occurs, it cannot be treated with standard cough medicines and requires a physical swap to an alternative drug class (like Losartan).

Safety Warning: POTENT CARDIOVASCULAR ANTI-HYPERTENSIVE & ACE INHIBITOR. For Physician and Cardiologist Supervision Only. The Fetal Toxicity Mandate: ABSOLUTELY CONTRAINDICATED IN PREGNANCY. Drugs acting directly on the renin-angiotensin system chemically induce severe fetal renal damage, skull hypoplasia, and neonatal death if taken during the second and third trimesters; stop therapy immediately if pregnancy is detected. Angioedema Alert: If a patient presents with sudden physical swelling of the face, lips, tongue, or glottis (angioedema), stop administration immediately as it physically blocks airways. Contraindications: Absolute contraindications in patients with a history of angioedema related to previous ACE inhibitor treatment, bilateral renal artery stenosis, pregnancy, or concurrent use of Aliskiren in diabetic patient profiles.

Global CDMO Services & Wholesale Supply Chain

Healthy Life Pharma Private Limited and Healthy Inc provide complete, internationally validated Third-Party Contract Manufacturing (CDMO Services) and bulk private-label export supply for the entire Lisinopril dosage spectrum. Because this molecule faces zero controlled-substance dual-licensing regulatory hurdles, our high-capacity lines can rapidly manufacture, release, and ship multi-container shipping loads. We deliver all required compliance documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Zone IVb Stability Reports, and Complete CTD Format Dossier sets) for rapid entry registration.

Commercial & Bulk Procurement Inquiries:

• Corporate Head Office: Mumbai, Maharashtra, India

• Primary Manufacturing Base: Boisar, Maharashtra, India

• WhatsApp / Direct Call: +91 7710003340

• Corporate Email: info@healthyinc.co.in